Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on February 27, 2026 reporting Item 8.01 (Other Events). Voluntary pause of Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome hyperphagia: a major clinical setback.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Voluntary pause of Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome hyperphagia: a major clinical setback
- Trial suspension signals potential safety signal, enrollment issue, or regulatory concern; reason not disclosed in Item 8.01
- Phase 3 halt is high-stakes: PWS is a rare disease with no approved hyperphagia treatment, making ARD-101 a key pipeline asset
- Investors should review Exhibit 99.1 press release for root cause, timeline for resumption, and any FDA involvement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.